
|Videos|June 9, 2020
SARS-CoV-2 Vaccine: Does Nucleocapsid DNA Lead to Lasting Protection?
Author(s)Grant M. Gallagher
Patrick Soon-Shiong, MD, explains why an ImmunityBio SARS-CoV-2 vaccine candidate uses Nucleocapsid DNA alongside Spike DNA.
Advertisement
Segment Description: Patrick Soon-Shiong, MD, Chairman & CEO of ImmunityBio, explains why the firm's SARS-CoV-2 vaccine candidate uses Nucleocapsid DNA alongside Spike DNA.
Newsletter
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.
SubscribeAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Contagion Live
1
FDA Assigns Highest-Risk Classification to Salmonella Egg Recall
2
Update on Cyclosporiasis: Over 15,000 Cases, Expands to 47 States
3
Why Measles Cases Are Up: US Childhood Vaccine Rates Drop, Immunization Exemptions Increase
4
What Are the Legalities of the Executive Order on Childhood Vaccines?
5








































































































































